{
    "clinical_study": {
        "@rank": "127601", 
        "arm_group": [
            {
                "arm_group_label": "ONO-8539 BID", 
                "arm_group_type": "Experimental", 
                "description": "ONO-8539"
            }, 
            {
                "arm_group_label": "Placebo BID", 
                "arm_group_type": "Placebo Comparator", 
                "description": "0mg"
            }
        ], 
        "brief_summary": {
            "textblock": "A study to investigate the efficacy of ONO-8539 on acid-induced oesophageal hypersensitivity\n      in healthy male adult volunteers."
        }, 
        "brief_title": "A Study to Investigate the Effect of ONO-8539 on Acid-Induced Oesophageal Hypersensitivity in Healthy Volunteers", 
        "condition": "Acid Reflux", 
        "condition_browse": {
            "mesh_term": [
                "Gastroesophageal Reflux", 
                "Hypersensitivity"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomised, double-blind, placebo-controlled, two-period crossover study, to\n      investigate the efficacy of ONO-8539 on acid-induced oesophageal hypersensitivity in healthy\n      male adult volunteers. Each subject will be randomised to ONO-8539 or placebo twice daily in\n      the first treatment period and the alternate treatment in the second treatment period.\n      Dosing in each period will be for 15 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy Caucasian male subjects, aged 18-45 years inclusive, will be entered into\n             this study.\n\n        Exclusion Criteria:\n\n          -  Subjects will be excluded if they have a motility disorder, are not able to tolerate\n             study procedures or have had GI surgery or have a condition that would affect the\n             study results."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01705275", 
            "org_study_id": "ONO-8539POE012"
        }, 
        "intervention": [
            {
                "arm_group_label": "ONO-8539 BID", 
                "description": "ONO-8539", 
                "intervention_name": "ONO-8539", 
                "intervention_type": "Drug", 
                "other_name": "ONO-8539 acid hypersensitivity"
            }, 
            {
                "arm_group_label": "Placebo BID", 
                "description": "Identical to ONO-8539 tablet but without active ingedient", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other", 
                "other_name": "0mg ONO-8539"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "E1 2AJ"
                }, 
                "name": "London Clinical site Recruiting"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Double-blind, Placebo-controlled, Two-period Crossover Study to Investigate the Effect of ONO-8539 on Acid-induced Oesophageal Hypersensitivity in Healthy Male Adult Volunteers", 
        "overall_official": {
            "affiliation": "Clinical Department, Ono Pharmaceutical Co. Ltd", 
            "last_name": "Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Area under the curve (AUC) of the change from baseline in pain threshold in the proximal oesophagus following electrical stimulation after oesophageal acid infusion.", 
            "safety_issue": "No", 
            "time_frame": "15 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01705275"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the Curve (AUC) of the change from baseline in pain threshold in the distal oesophagus following electrical stimulation after oesophageal acid infusion", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }, 
            {
                "measure": "Maximum change from baseline in pain threshold in the proximal and distal oesophagus following electrical stimulation after oesophageal acid infusion.", 
                "safety_issue": "No", 
                "time_frame": "15 days"
            }, 
            {
                "measure": "Change in absolute pain threshold from baseline in the proximal and distal oesophagus and somatic control following electrical stimulation after oesophageal acid infusion at each time point.", 
                "safety_issue": "No", 
                "time_frame": "15 Days"
            }, 
            {
                "measure": "Change from baseline at each time point in subject reported pain following electrical stimulation after oesophageal acid infusion using the short-form McGill pain questionnaire (SF-MPQ).", 
                "safety_issue": "No", 
                "time_frame": "15 Days"
            }, 
            {
                "measure": "Relationship between the pharmacokinetics of ONO-8539 and change from baseline in pain threshold in the proximal oesophagus following electrical stimulation after oesophageal acid infusion.", 
                "safety_issue": "No", 
                "time_frame": "15 Days"
            }, 
            {
                "measure": "Relationship between State Trait Anxiety Inventory (STAI)-state score and change from baseline in pain threshold in the proximal oesophagus following electrical stimulation after oesophageal acid infusion.", 
                "safety_issue": "No", 
                "time_frame": "15 Days"
            }, 
            {
                "measure": "Safety and tolerability: adverse events, physical examination, body weight, vital signs, 12-lead Electrocardiogram (ECG) and safety laboratory evaluations.", 
                "safety_issue": "Yes", 
                "time_frame": "15 Days"
            }, 
            {
                "measure": "The maximum observed plasma concentrations (Cmax), time to reach Cmax (Tmax), area under the curve (AUC), and trough concentration of ONO-8539 prior to dosing.", 
                "safety_issue": "No", 
                "time_frame": "15 Days"
            }
        ], 
        "source": "Ono Pharmaceutical Co. Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ono Pharmaceutical Co. Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}